

\*Please provide your CV of 1-2 pages in length including details of the following items. This will be posted on the conference website.

- **Full Name:** Sun Min Lim
- **Current Position & Affiliation:** Associate Professor , Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Republic of Korea
- **Country:** Republic of Korea

• **Educational Background:**

2010.9 ~ 2017.2 Doctor of Philosophy, Yonsei University Graduate School  
 2002.3 ~ 2008.2 College of Medicine, Yonsei University, Seoul, Republic of Korea  
 2006.1 ~ 2006.2 Washington University School of Medicine, St Louis, Missouri (Visiting student)

• **Professional Experience:**

2008.3 ~ 2009.2 Internship, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea  
 2009.3 ~ 2013.2 Residency in Internal Medicine. Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea  
 2012.3~ 2013.2 Chief medical resident, Department of Internal medicine, Severance Hospital  
 2013.3~2015.8 Fellow, Division of Medical Oncology, Department of Internal Medicine, Severance Hospital  
 2015.9~2020.2 Assistant Professor, CHA Bundang Medical Center, CHA University  
 2020.3~ 2023.2 Assistant Professor, Severance Hospital, Yonsei University Health System  
 2023.3~ Associate Professor, Severance Hospital, Yonsei University Health System

• **Professional Organizations:**

2012~ Member, American Society of Clinical Oncology  
 2012~ Member, American Association of Cancer Research  
 2012~ Member, Korean Association for Clinical Oncology  
 2012~ Member, Korean Cancer Study Group  
 2013~ Member, International Association for the Study of Lung Cancer

• **Main Scientific Publications:**

1. Lim SM\*, Kim HR\*, Lee JS, et al. An open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol 2017;35(23):2613-2618.
2. Yun MR\*, Lim SM\*, et al. Enhancer remodeling and microRNA alterations are associated with acquired resistance to ALK inhibitors. Cancer Res 2018; 78(12):3350-3362.
3. Pyo K-H\*, Lim SM\*, Park C-W\*, et al. Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer. Journal for ImmunoTherapy of Cancer 2020;8:e000970.

4. Lim SM, Kim CG, Lee JB and Cho BC. Patritumab Deruxtecan: Paving the way for EGFR-TKI-resistant NSCLC. *Cancer Discov* 2022; 12(1): 16-19.
5. Oh SY, ...Lim SM\*, Yun MR. Preclinical study of a biparatopic METxMET antibody-drug conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC. *Clinical Cancer Res* 2022